On May 6, 2008, Genedata, a leading provider of solutions for computational biology, announced the release of Genedata Expressionist® 5.0, its enterprise high-throughput biomarker discovery platform.
Identifying and validating biomarkers with the highest degree of confidence has become key for drug safety and efficacy prediction in preclinical development. Doing this effectively necessitates the seamless integration of transcriptomics, proteomics, metabolomics and clinical chemistry data.
Supporting a wide array of omics technologies, Genedata Expressionist 5.0 easily handles the ever-increasing throughput, size and complexity of datasets to perform truly integrated analysis. The new release provides significantly enhanced data processing and management features for quantitative and qualitative biomarker development:
Dr. Othmar Pfannes, CEO of Genedata, said, “As life science research faces data sets of steadily growing size and complexity, we are proud to rise to the challenge with the new version of our Expressionist enterprise software platform. Driven by the innovative interaction with our customers in developing new integrative, workflow-based data processing features, Expressionist 5.0 exceeds in performance as well as in sophistication.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.